Back to today’s briefing

Story perspectives

Eli Lilly's Retatrutide: Breakthrough Weight Loss for Diabetes

3/20/2026

32 2 Full Breakdown

Summary

Story summary

Eli Lilly and Company’s retatrutide, in a Phase 3 trial for type 2 diabetes, significantly lowers A1C by 1.7% to 2.0% and outperforms placebo.
Over 40 weeks, participants lost an average of 15.3% of weight, with a maximum loss of 16.8% among completers.
Nausea and diarrhea were side effects, and about 5% of participants discontinued.
Lilly plans to submit retatrutide for obesity approval this year and for diabetes in 2027.

1 of 1

Story summary

Eli Lilly and Company’s retatrutide, in a Phase 3 trial for type 2 diabetes, significantly lowers A1C by 1.7% to 2.0% and outperforms placebo.
Over 40 weeks, participants lost an average of 15.3% of weight, with a maximum loss of 16.8% among completers.
Nausea and diarrhea were side effects, and about 5% of participants discontinued.
Lilly plans to submit retatrutide for obesity approval this year and for diabetes in 2027.